2019 novel coronavirus disease covid 19
play

2019 novel coronavirus disease (COVID-19) for Advances in Internal - PowerPoint PPT Presentation

2019 novel coronavirus disease (COVID-19) for Advances in Internal Medicine 2020 George W. Rutherford, M.D., A.M. Salvatore Pablo Lucia Professor of Epidemiology, Preventive Medicine, Pediatrics and History Head, Division of Infectious Disease


  1. 2019 novel coronavirus disease (COVID-19) for Advances in Internal Medicine 2020 George W. Rutherford, M.D., A.M. Salvatore Pablo Lucia Professor of Epidemiology, Preventive Medicine, Pediatrics and History Head, Division of Infectious Disease and Global Epidemiology Department of Epidemiology and Biostatistics School of Medicine Institute for Global Health Sciences University of California, San Francisco 17 June 2020

  2. What we’ll discuss this morning • Human coronaviruses in general, SARS, MERS and the novel coronavirus, SARS-CoV-2 • The emergence of SARS-CoV-2 and its associated disease (COVID-19) in Wuhan, China • Current epidemiology • Some historical and current perspectives on face coverings

  3. Human coronaviruses, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS) and the novel 2019 coronavirus

  4. Coronaviruses • Before SARS (2002), coronaviruses were considered relatively inconsequential pathogens that caused common colds • Four human coronaviruses are endemic globally and cause 10-30% of upper respiratory tract infections in adults (alpha coronaviruses HCoV 2229E, NL 63, OC 43, HKU 1) • Widely distributed in mammals and birds • Since 2002 we’ve recognized two highly pathogenic strains that causes severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)

  5. SARS and MERS • As opposed to the human coronaviruses that are associated with upper respiratory tract infections, SARS and MERS are caused by beta coronaviruses • Primarily cause lower respiratory tract infection (pneumonia) • Relatively high case fatality rates SARS MERS Cases 8098 2494 Deaths 774 858 Case fatality rate 9.5% 34.4% Controlled Yes after reached pandemic No, continued transmission Other features 58% from nosocomial transmission 70% of cases from nosocomial transmission

  6. SARS and MERS • Both closely related to bat SARS strains of coronavirus • Transmitted through other secondarily infected species • SARS Himalayan palm civets SARS-CoV-2 • MERS dromedaries • SARS originally associated with wet market in MERS Guangzhou • 26 countries • $10-$30B economic damage From: Lu R, Li J, N P, et al. Genomic characterisation of and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020 Jan 29 [Epub ahead of print].

  7. SARS-CoV-2 Binding site • Spike (S) protein binds to angiotensin- converting enzyme 2 (ACE2) on the membranes of lung alveolar cells, upper airway epithelial cells and glandular cells of the GI tract

  8. Emergence of SARS-CoV-2 and its associated disease (COVID-19 in Wuhan, China

  9. Emergence of the 2019 novel coronavirus (SARS- CoV-2) • First case (COVID-19) hospitalized 17 December 2019 • Cluster reported on 30 December • Huanan Wholesale Seafood Market closed 1 January • COVID-19 isolated 7 January • COVID-19 sequenced 10 January • Rapid diagnostic tests developed and distributed • Cordon sanitaire implemented in Wuhan and surrounding cities on 23 January – 59 million people quarantined • WHO declared Public Health Emergency of International Concern 30 January • Outbreak grew from a handful of cases exposed at Huanan wholesale seafood market to more than 2.5 million cases and 180 000 deaths in less than 4 months with ongoing person-to-person transmission primarily via respiratory droplet

  10. Epizoology of COVID-19 • Genetic sequence close to bat strains of coronavirus • Suggestion of a secondary host, which acquired COVID- 19 from bats and transmitted it to humans at Huanan Wholesale Seafood Market • Possible candidate is the pangolin , a mammal whose scales used in traditional medicine • Most illegally trafficked animal in the world

  11. COVID-19 cases by date of onset and date of report, China 2018-2019* *Through 1 March 2020

  12. Transmission dynamics of COVID-19, China • The majority of cases arose from close contacts of symptomatic cases • 1.5% of close contacts in China developed COVID-19 • Transmission was driven by family clusters (75-85% of infected contacts) • Secondary household attack rates with ~10% early in the outbreak and fell to 3% with faster isolation • Transmission in closed settings happened but was not a major driver in China (health facilities, nursing homes, prisons) • Transmission in schools was not been observed in China; this may simply be because of the closure of schools during most of the outbreak • Did China underreport deaths, especially in the waning days of the epidemic?

  13. Modeling unreported cases, Wuhan • Wang and colleagues modeled • Major findings: R e decreased the epidemiology of 25,961 from 3.86 to 0.32 over the four laboratory-confirmed cases in periods Wuhan through 18 February • Examined four periods: 1-10 January, 11-22 January, 23 January-1 February (first week of lockdown) and 2-18 February • 59% of cases were unascertained • “Unascertained” = undiagnosed because they were asymptomatic or mildly symptomatic Wang C, Liu L, Hao X, et al. Evolving epidemiology and impact of non-pharmaceutical interventions on the outbreak of coronavirus disease 2019 in Wuhan, China. medRxiv 2020 Mar 3 [Epub ahead of print].

  14. Prevalence of SARS-CoV-2 asymptomatic infection Oran DP, Topol EJ, Prevalence of asymptomatic SARS-CoV-2 infection. A narrative review. Ann Intern Med 2020 [Epub ahead of print].

  15. Is health-care resource availability associated with COVID-19 mortality? Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability [Letter]. Lancet Global Health 2020 Feb 25 [E pub ahead of print].

  16. Worobey M, Pikar J, Larsen B, et al. The emergence of SARS-Co-V-2 in Europe and the US. bioRxiv 2020 May 23.

  17. COVID-19 cases and deaths, United States, 2020 1,956,499 cases 110,932 deaths

  18. COVID-19 cases by county, California, 2020

  19. COV OVID-19 cases es by week eek. San F Francisco C County ty 400 Shelter in place 341 350 304 300 285 276 251 250 232 228 194 191 189 200 148 150 100 68 50 32 8 0 0 0 0 0 0 27-Jan 3-Feb 10-Feb 17-Feb 24-Feb 2-Mar 9-Mar 16-Mar 23-Mar 30-Mar 6-Apr 13-Apr 20-Apr 27-Apr 4-May 11-May 18-May 25-May 1-Jun

  20. COV OVID-19 cases es by week eek. Bay Ar Area Counties 1800 Shelter in place 1622 1600 1397 1389 1373 1400 1270 1226 1200 1116 1080 1069 978 1000 906 800 600 490 400 184 200 50 2 6 0 0 0 0 27-Jan 3-Feb 10-Feb 17-Feb 24-Feb 2-Mar 9-Mar 16-Mar 23-Mar 30-Mar 6-Apr 13-Apr 20-Apr 27-Apr 4-May 11-May 18-May 25-May 1-Jun

  21. Infectious disease deaths, United States, 1900- 1996 Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20 th century. JAMA 1999; 281:61-66.

  22. Two strategic goals • Limit new cases by decreasing R e , the effective reproductive number • Flatten and prolong the outbreak to (1) assure adequacy of health care resources and (2) buy time for antivirals and eventually vaccine

  23. Effective reproductive number (R e ) Courtesy of Dr. Wan Yang, Columbia University

  24. Effects of pandemic mitigation on health care needs

  25. COVID-19 cases by day, Lodi and Bergamo Empirical evidence that social provinces, Italy, February-April, 2020 800 distancing works INTERVENTION INTERVENTION 700 • Two adjacent Italian provinces in Lombardy region 600 • One (Lodi) began shelter-in-place on Recalculation 500 of prior weeks 26 February 419 cases 400 • Other (Bergamo) began shelter-in- place on 9 March 300 • Empirical evidence that shelter in 200 place orders can blunt transmission and new disease 100 0 26-Feb 5-Mar 13-Mar 21-Mar 29-Mar 6-Apr 14-Apr 22-Apr 30-Apr 8-May 16-May 24-May 1-Jun 26-Feb 5-Mar 13-Mar 21-Mar 29-Mar 6-Apr 14-Apr 22-Apr 30-Apr 8-May 16-May 24-May 1-Jun Lodi Bergamo https://www.ilsole24ore.com/art/coronavirus-dati-lodi-dimostrano-misure-lockdown-rallentano-contagio-ADo675B

  26. Is social distancing working in San Francisco? COVID-19 cases by day, San Francisco and Los Angeles, March-June, 2020 San Francisco Los Angeles 2500 1600 Shelter in place Shelter in place 1400 2000 1200 1000 1500 800 1000 600 First COVID-19 death First COVID-19 death 400 500 200 0 0

  27. San Francisco and the 1918-19 influenza epidemic

  28. Comparative excess mortality per 100 000 by days since 7 September 1918, United States Predicted excess mortality PH closures, masks Actual excess mortality Bootsma MCJ, Ferguson MN. The effect of public health measures on the 1918 influenza pandemic in U.S. cities. Proc Natl Acad Sci 2007; 104:7488-93.

  29. Kimberly A. Prather et al. Science 2020;science.abc6197

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend